Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)
A 4-Year Follow-up, Blinded-Outcomes Trial of Subjects Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202
Sponsor: InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Listed as NCT02033096, this observational or N/A phase trial focuses on Jaundice and Neonatal Hyperbilirubinemia and remains completed. Sponsored by InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company, it has been updated 10 times since 2008, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Nov 2019 — Jan 2021 [monthly]
Completed
-
Sep 2019 — Nov 2019 [monthly]
Completed
▶ Show 5 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: PHASE2 → None
-
Feb 2018 — Apr 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.